Login to Your Account

In The Clinic NEWS

Oncogenex Pharmaceuticals Inc. reported that a combination of its lead anticancer candidate apatorsen and the chemotherapy docetaxel met the primary endpoint of overall survival in the investigator-sponsored phase II Borealis-2 trial.

Dipexium Pharmaceuticals Inc. is still sorting through data from a pair of identical phase III trials, but top-line findings in mild infections of diabetic foot ulcers with the company's lead – and only – product did nothing to encourage investors, and shares tumbled 78 percent.

Aduro Biotech Inc. CEO Stephen Isaacs said the company suspects "more of a port issue" than anything else with the latest problem in pancreatic cancer trials with products based on the Listeria-based immunotherapy construct platform.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: